Lead: On 1 December 2025 the World Health Organization warned that a global shortage of glucagon‑like peptide‑1 (GLP‑1) weight‑loss drugs such as Mounjaro and Ozempic threatens to slow efforts to curb rising obesity and its complications. WHO officials said the medicines represent a “new chapter” in treating obesity because of clear evidence they help people lose weight and reduce related disease risks. However, constrained production and high prices mean at most about 100 million people can access the drugs now — roughly 10% of the estimated 1 billion worldwide who could benefit. The agency urged countries and manufacturers to expand supply and lower costs while reminding clinicians that the medicines are not suitable for everyone, including pregnant women.
Key takeaways
- WHO published a special communication on 1 December 2025 saying GLP‑1 therapies are an important clinical innovation for obesity treatment.
- Current global production can reach roughly 100 million people, about 10% of the ~1 billion adults who might benefit from these drugs.
- Obesity (BMI ≥30) is projected to rise from 1 billion to 2 billion people by 2030, with economic costs forecast to reach $3 trillion by the same year.
- WHO’s guidance emphasizes that pregnant women should not use GLP‑1 drugs and that medication should be paired with diet, exercise and counselling.
- Three barriers limit global access: manufacturing capacity and affordability, health‑system readiness to deliver therapy, and universal health coverage.
- WHO authors of the communication include Francesca Celletti, Luz De Regil and Jeremy Farrar; WHO director‑general Dr Tedros Adhanom Ghebreyesus highlighted the drugs’ population health potential.
- Advocacy groups, including the Obesity Health Alliance led by Katherine Jenner, stress supply fragility, targeted public coverage and the need for comprehensive support to avoid rapid weight regain after treatment stops.
Background
GLP‑1 receptor agonists — drugs originally developed for type 2 diabetes — have produced substantial weight loss in clinical trials and routine use, prompting clinicians and policymakers to rethink obesity treatment. The rapid rise in demand has outpaced manufacturers’ capacity: large pharmaceutical producers report supply constraints even as off‑label and branded use expands in high‑income countries. The WHO framed obesity increasingly as a chronic, preventable and treatable disease rather than solely a lifestyle issue, reflecting a shift in medical and policy discourse over the past decade.
Global obesity prevalence has risen sharply in recent decades, driven by demographic change, urbanization, dietary shifts and sedentary lifestyles. Health systems vary widely in their ability to deliver long‑term pharmacotherapy, from countries with structured specialist services to settings where primary care lacks obesity management resources. Price and reimbursement policies are likewise inconsistent: in many lower‑income countries the drugs are effectively unavailable because of cost and supply, while in wealthier systems access is often rationed to patients meeting strict clinical criteria.
Main event
The WHO issued a special communication, published in the Journal of the American Medical Association, that endorses GLP‑1 therapies as a significant therapeutic advance but warns that global access is limited. The agency said the medicines can reduce weight and lower the risk of comorbid events — including heart attack, stroke, type 2 diabetes and sleep apnoea — but must be integrated into broader care packages. The communication was authored by Francesca Celletti, Luz De Regil and Jeremy Farrar; their paper stresses both the clinical promise and the systemic obstacles to equitable distribution.
WHO quantified the shortfall: at present manufacturing limits and supply chain constraints mean only about 100 million people could realistically receive GLP‑1 drugs, far short of the approximately 1 billion people worldwide who meet clinical criteria for benefit. The agency recommended urgent steps to expand production, negotiate lower prices, and develop delivery models so health systems can safely prescribe and monitor therapy. It also reiterated clinical cautions: pregnant people should not use GLP‑1 drugs and treatment should be part of multidisciplinary care that includes nutritional and behavioral support.
WHO director‑general Dr Tedros framed the drugs as part of a broader policy shift: while not a standalone solution, they can help millions overcome obesity-related harms if deployed equitably. At the same time, the agency highlighted three major barriers to universal access — production and affordability, health‑system readiness, and broader access to care — and called on governments, manufacturers and international partners to act in concert.
Analysis & implications
The WHO position signals a potential turning point in global obesity policy, forcing countries to confront trade‑offs between managing demand, funding high‑cost therapies and strengthening prevention. If manufacturers scale up production and lower prices, these drugs could reduce the incidence of obesity‑related complications and associated health spending in the medium term; yet such scale‑up requires major investment, technology transfer and likely voluntary licensing or new manufacturing lines. Without those steps, the benefit will be concentrated in wealthier populations and health inequities may widen as poorer countries remain excluded.
From a clinical perspective, integrating GLP‑1 therapies into routine care demands workforce training, monitoring capacity and long‑term follow‑up, because evidence shows weight commonly returns after treatment cessation. Health systems that lack obesity specialists must decide whether to route prescribing through primary care with decision support, specialist hubs, or hybrid models — each with different cost and governance implications. Reimbursement criteria will shape who receives treatment; narrow public coverage risks amplifying private market demand and driving up prices further.
Economically, WHO’s $3 trillion projection for obesity costs by 2030 underlines the stakes. If GLP‑1 drugs can avert even a fraction of obesity‑related cardiovascular and metabolic disease, they may produce downstream savings; however, those savings are uncertain and accrue over years, while drug expenditure is immediate. Policymakers must therefore weigh short‑term budget impact against potential long‑term health gains and design procurement strategies — pooled purchasing, price ceilings, tiered pricing or generic pathways — to improve affordability.
Comparison & data
| Metric | Current | Projected 2030 |
|---|---|---|
| People eligible who could benefit | ~1,000,000,000 | — |
| People who can access drugs now (est.) | ~100,000,000 | Depends on scale‑up |
| Global obesity prevalence (BMI ≥30) | 1,000,000,000 | 2,000,000,000 |
| Estimated global economic cost of obesity | — | $3,000,000,000,000 by 2030 |
The table contrasts current reach with population needs and projected burden through 2030. It shows a stark mismatch between the roughly 100 million people who could access therapy today and the billion who may benefit, and it highlights the scale of the challenge if prevalence doubles and economic costs rise as projected. This gap frames WHO’s call for manufacturing expansion and pricing reforms to avoid exacerbating global health inequities.
Reactions & quotes
WHO officials positioned the communication as guidance for clinicians and policymakers rather than a blanket recommendation for universal use. The agency emphasized both benefit and caution, noting the need for concurrent lifestyle and behavioural support to sustain outcomes after pharmacotherapy.
“While medication alone won’t solve this global health crisis, GLP‑1 therapies can help millions overcome obesity and reduce its associated harms.”
Dr Tedros Adhanom Ghebreyesus, WHO director‑general
Advocacy groups welcomed wider clinical recognition of obesity as a treatable chronic disease but warned that supply constraints and narrow public funding will limit impact. In the UK, the Obesity Health Alliance stressed the importance of combining drugs with structured support and cautioned against assuming indefinite medication as a solution.
“Access is still limited, supply is fragile, and public use is tightly targeted; these medicines help individuals but must be paired with comprehensive support.”
Katherine Jenner, executive director, Obesity Health Alliance
Academic and manufacturing stakeholders highlighted practical steps: accelerate manufacturing, enable technology transfer to expand capacity, and negotiate pricing mechanisms that preserve incentives for innovation while improving affordability. Experts also reiterated safety limits, particularly the contraindication in pregnancy.
“These therapies represent a tipping point in treatment, but equitable rollout will require coordinated policy and manufacturing action.”
Jeremy Farrar, WHO assistant director (author of special communication)
Unconfirmed
- The precise timeline for large‑scale production expansion by manufacturers is not yet public and remains uncertain.
- The degree to which global prices will fall, and on what timetable, depends on negotiations and policy actions that are not yet confirmed.
- Long‑term cardiovascular outcome reductions in broader, real‑world populations beyond trial participants require further confirmation with extended follow‑up studies.
Bottom line
WHO’s statement recognizes GLP‑1 weight‑loss drugs as an important medical advance with real potential to reduce obesity and related diseases, but it also warns that current supply and affordability constraints will limit global benefit. Policymakers face difficult choices: act now to scale manufacturing, negotiate prices and prepare health systems for safe delivery, or risk concentrating benefits in wealthier populations and widening health inequities.
For clinicians, the guidance reinforces the need to integrate pharmacotherapy into multidisciplinary care and to apply safety exclusions such as pregnancy. For governments and manufacturers, the immediate priorities are expanding production capacity, exploring pooled procurement or licensing options, and ensuring that access decisions are guided by evidence and equity.
Sources
- The Guardian — media report summarising WHO communication and reactions.
- JAMA — academic journal (special communication publishing WHO authors’ analysis).
- World Health Organization — official (WHO guidance and statements).